迟发性运动障碍的治疗
Treatment of Tardive Dyskinesia.
作者信息
Bashir Hassaan H, Jankovic Joseph
机构信息
Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center and Movement Disorders Clinic, 7200 Cambridge, 9th Floor, Suite 9A, Houston, TX 77030-4202, USA.
Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center and Movement Disorders Clinic, 7200 Cambridge, 9th Floor, Suite 9A, Houston, TX 77030-4202, USA.
出版信息
Neurol Clin. 2020 May;38(2):379-396. doi: 10.1016/j.ncl.2020.01.004. Epub 2020 Feb 28.
Tardive dyskinesia (TD) is an iatrogenic condition that encompasses a wide phenomenological spectrum of movement disorders caused by exposure to dopamine receptor blocking agents (DRBAs). TD may cause troublesome or disabling symptoms that impair quality of life. Due to frequent, often inappropriate, use of DRBAs, TD prevalence rates among patients exposed to DRBAs continue to be high. The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission. Dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered the treatment of choice of TD.
迟发性运动障碍（TD）是一种医源性疾病，其涵盖了因接触多巴胺受体阻断剂（DRBAs）而引发的广泛的运动障碍现象学谱。TD可能导致令人烦恼或致残的症状，从而损害生活质量。由于DRBAs的频繁使用（往往是不恰当的使用），接触DRBAs的患者中TD的患病率仍然很高。明智地使用DRBAs是预防TD、减轻疾病负担和实现持久缓解的关键。多巴胺耗竭性囊泡单胺转运体2抑制剂被认为是TD的首选治疗方法。
Zotero 插件